Skip to main content

Security report for krka.by

KRKA, tovarna zdravil, d.d., Novo mesto · Healthcare · Belarus

Partial score · DNS & email only

57/100

0–100, higher is better. How it is calculated

KRKA, tovarna zdravil, d.d., Novo mesto is a well-established pharmaceutical company specializing in the development, manufacturing, and sales of generic, over-the-counter, veterinary, and dietary supplement products. With nearly 70 years of experience, the company holds a strong market position as a leading global generic pharmaceutical manufacturer. The website targets healthcare professionals, consumers, and veterinary sectors primarily in Belarus and globally through multiple localized domains. The business model focuses on high-quality pharmaceutical products supported by a robust corporate presence and strategic international footprint. Technically, the website is built on modern frameworks such as Nuxt.js, employs industry-standard analytics tools, and demonstrates good mobile optimization and accessibility. Security posture is strong with HTTPS enforcement and cookie consent mechanisms, though some security headers and incident response disclosures could be improved. Overall, the site reflects a professional and trustworthy corporate image with comprehensive privacy and cookie policies, clear contact information, and consistent branding.

Scanned

3 of 7 checks could not complete. The site may be unreachable or blocking automated scans, so the results below cover only what could be checked. Try a rescan later.

NIS2 and GDPR posture

NIS2 outside view
Not assessed
GDPR outside view
Not assessed

Both readouts depend on the site's pages, which could not be loaded in this scan.

Priority findings

2 findings rated critical or high. Fix these first.

  1. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

  2. Network security

    Services reachable from the internet are the first thing attackers probe. Anything open that does not need to be should be closed.

    • High

      High-Risk Service Exposed: FTP

      Port 21 (FTP) is publicly accessible - FTP - Often unencrypted file transfer

      What to do: Consider restricting access to FTP or implementing strong authentication

      • NIS2 21(2)(e)
      • IR 2024/2690 6.7.2(f): Implementing Regulation (EU) 2024/2690, Annex point 6.7.2(f): Network security
      • NIST CM-7: NIST SP 800-53 Rev. 5 CM-7: Least Functionality
      • NIST SC-7: NIST SP 800-53 Rev. 5 SC-7: Boundary Protection

Need hands-on remediation? Email guard@offseq.com

Keep watching krka.by

This scan found 14 issues across 4 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
62
Email security
70
DNS health
75
Network security
20
Average
57

Not counted

  • Security headers: did not complete in this scan.
  • GDPR outside view: did not complete in this scan.
  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

KRKA operates in the healthcare sector with a focus on pharmaceuticals, including generics and veterinary products. The company leverages a global network of localized websites to serve diverse markets, indicating a mature international business model. Revenue streams are primarily from pharmaceutical sales, supported by strong R&D and manufacturing capabilities. The company emphasizes sustainability and corporate responsibility, as reflected in dedicated ESG content. The presence of multiple country-specific domains and partner sites demonstrates a broad partnership ecosystem. Growth indicators include recent business results announcements and strategic content highlighting innovation and quality. The company maintains a professional digital presence aligned with its market leadership and regulatory compliance requirements.

Security posture

The website exhibits a mature security posture with HTTPS enabled and a comprehensive cookie consent mechanism that allows users to manage preferences. Analytics scripts are loaded asynchronously to minimize performance impact. However, the absence of explicit security headers such as Content-Security-Policy and lack of a published incident response or vulnerability disclosure page represent areas for improvement. No exposed sensitive data or vulnerable libraries were detected in the HTML content. The site does not currently provide a security.txt file or dedicated security contact channels, which could enhance transparency and incident handling readiness. Overall, the security practices align well with industry standards for corporate pharmaceutical websites but could benefit from enhanced security header implementation and incident response visibility.

Recommendations

  1. Publish a dedicated incident response page or contact email to improve transparency and readiness.
  2. Implement security headers such as Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options.
  3. Regularly audit and update third-party scripts to mitigate potential vulnerabilities.
  4. Consider adding a security.txt file to facilitate vulnerability disclosures.
  5. Enhance data retention policy disclosures to align with GDPR and user expectations.

Contact details published on the site

Addresses
Legal name
Акционерное общество "KRKA, tovarna zdravil, d.d., Novo mesto"
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
KRKA, tovarna zdravil, d.d., Novo mesto
Description
КРКА – одна из ведущих дженериковых фармацевтических компаний с почти 70-летним опытом работы. Сегодня высокое качество нашей продукции признано во всем мире.
Key services
Development, Manufacturing, Sales of prescription drugs, Sales of OTC drugs, Sales of veterinary products, Sales of dietary supplements
Content quality
good
Branding
consistent

Technology

Stack
JavaScript, Google Analytics, Google Tag Manager, Yandex Metrika, Swiper.js, Typekit Fonts
Frameworks
Nuxt.js
Performance
moderate
Mobile
good
Accessibility
good
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent banner with granular controls
  • No exposed sensitive data in HTML
  • Use of async loading for analytics scripts

Analytics and tracking

Services
Google Analytics, Google Tag Manager, Yandex Metrika
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Yandex Metrika
Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenges.
  2. Content is professionally presented in Russian targeting Belarus market.
  3. Strong corporate branding and consistent messaging about pharmaceutical business.
  4. Comprehensive cookie consent mechanism implemented.
  5. Multiple external domains linked, representing global presence.
  6. No explicit security incident response or vulnerability disclosure pages found.
  7. Use of modern JavaScript frameworks and analytics tools.
  8. Contact information is clear and includes physical address, phone, and email.
  9. No suspicious or malicious content detected.
Technical notes

Notes

The website is built using Nuxt.js, a modern Vue.js framework, ensuring good performance and SEO capabilities. It uses asynchronous loading for analytics scripts including Google Analytics, Google Tag Manager, and Yandex Metrika, which supports efficient data collection without blocking page rendering. The site employs Typekit fonts for consistent typography and Swiper.js for interactive slideshows. Mobile optimization and accessibility features such as skip links and font size controls are present, enhancing user experience. The site performance is moderate, with room for optimization in resource loading and caching. No CMS was explicitly detected, suggesting a custom or headless CMS solution. Overall, the technical infrastructure supports a professional and scalable web presence suitable for a large pharmaceutical company.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with krka.by. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review krka.by.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.